N@N

EXEL, OME, CCRN, COKE, SGEN, IAG Expected To Be Down After Next Earnings Releases

May 6, 2013 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, May 7th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and June earnings reports. Exelixis Inc (NASDAQ:EXEL), Omega Protein Corp (NYSE:OME), Cross Country Healthcare Inc (NASDAQ:CCRN), Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE), SEATTLE GENETICS, INC. (NASDAQ:SGEN), IAMGOLD CORP (NYSE:IAG) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:

  Symbol  Company                          # of Reports         Quarter  Release Time
  EXEL    Exelixis Inc                     6 Quarter            Q1       After
  OME     Omega Protein Corp               May Earnings         Q1       After
  CCRN    Cross Country Healthcare Inc     6 Quarter            Q1       After
  COKE    Coca-Cola Bottling Co. Consolidated  12 Quarter           Q1       After
  SGEN    SEATTLE GENETICS, INC.           6 Quarter            Q1       After
  IAG     IAMGOLD CORP                     6 Quarter            Q1       After

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Exelixis Inc (NASDAQ:EXEL) - Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer. Its focuses on developing cabozantinib product candidate that inhibits MET, VEGFR2, and RET proteins, which are key drivers of tumor growth, vascularization, and/or metastasis. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma, and thyroid cancer. In addition, Exelixis, Inc. is involved in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies comprising Bristol-Myers Squibb Company; Sanofi; Genentech, Inc.; GlaxoSmithKline; Merck; and Daiichi Sankyo Company Limited. Its products under development through collaborations primarily include XL475 compound; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147 and XL765 PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California..

Omega Protein Corp (NYSE:OME) - Omega Protein Corporation operates as a nutrition and wellness company that delivers healthy products to the animal, human, and plant nutrition industries. Its marine product lines are sourced from menhaden, an Omega-3 rich fish harvested along the Atlantic and Gulf coasts. The company markets a line of omega-3 fish oil, protein-rich specialty fishmeal, and organic fish solubles for aquaculture, companion animal, livestock, and equine feed manufacturers. It produces ultra-refined, molecularly distilled omega-3 ingredients for human food manufacturers; and markets branded fish solubles as agronomic plant food. The company sells its products in the United States, Mexico, Europe, Canada, Asia, and South and Central America. Omega Protein Corporation was founded in 1913 and is headquartered in Houston, Texas..

Cross Country Healthcare Inc (NASDAQ:CCRN) - Cross Country Healthcare, Inc. provides healthcare staffing and outsourcing services to the healthcare market in Europe, the United States, Canada, and Asia. The company s Nurse and Allied Staffing segment provides nurse and allied staffing services; healthcare professionals in various specialties, such as operating room and radiology technicians, rehabilitation and respiratory therapists, radiation therapy technicians, nurse practitioners, and physician assistants; and registered nurses, licensed practical nurses, and certified nurse assistants for per diem assignments. This segment markets its nurse and allied staffing services primarily to acute care hospitals, health systems, public and private healthcare facilities, and for-profit and not-for-profit facilities under the Cross Country TravCorps, MedStaff Healthcare Solutions, NovaPro, Cross Country Local, CRU-48, Allied Health Group, and Assignment America names. Its Physician Staffing segment offers temporary physician staffing services. The company s Clinical Trial Services segment provides contract staffing and outsourcing, drug safety monitoring, and regulatory consulting services to pharmaceutical, biotechnology, and medical device companies, as well as contract research organization customers under the ClinForce, Assent, and AKOS brands. Its Other Human Capital Management Services segment offers education and training, as well as retained search services primarily related to physicians, allied health, and healthcare executives. The company was formerly known as Cross Country, Inc. and changed its name to Cross Country Healthcare, Inc. in May 2003. Cross Country Healthcare, Inc. was founded in 1996 and is headquartered in Boca Raton, Florida..

Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) - Coca-Cola Bottling Co. Consolidated, together with its subsidiaries, engages in the production, marketing, and distribution of nonalcoholic beverages, primarily products of The Coca-Cola Company. The company offers sparkling beverages, such as energy drinks; and still beverages, including bottled water, tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. It holds cola beverage agreements and allied beverage agreements, under which it produces, distributes, and markets sparkling beverage products of The Coca-Cola Company in certain regions. The company also distributes and markets still beverages of The Coca-Cola Company, such as POWERade, vitaminwater, and Minute Maid Juices To Go, as well as produces, distributes, and markets Dasani water products under still beverage agreements. In addition, it holds agreements to produce and market Dr Pepper. Further, the company distributes and markets various other products, including Monster energy products and Sundrop; and its own products, such as Country Breeze tea, Bean & Body coffee beverage, and Fuel in a Bottle power shots, as well as Tum-E Yummies, a vitamin-C enhanced flavored drink. Additionally, it produces beverages for other Coca-Cola bottlers; and provides restaurants and other immediate consumption outlets with fountain products. The company sells and distributes its products directly to retail stores and other outlets, including food markets, institutional accounts, and vending machine outlets. It operates in North Carolina, South Carolina, south Alabama, South Georgia, middle Tennessee, western Virginia, and West Virginia. The company was founded in 1902 and is based in Charlotte, North Carolina..

SEATTLE GENETICS, INC. (NASDAQ:SGEN) - Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company s ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington..

IAMGOLD CORP (NYSE:IAG) - IAMGOLD Corporation, a mid-tier gold mining company, engages in the exploration, development, and production of mineral resource properties. It primarily explores for gold, silver, zinc, copper, niobium, diamonds, and other metals. The company holds interests in five operating gold mines, a niobium mine, a diamond royalty, and exploration and development projects located in Africa and the Americas. Its development projects include the Westwood project located in the Abitibi region, Qu bec, Canada; and the Camp Caiman project located in northeastern French Guiana, South America. The company was formerly known as IAMGOLD International African Mining Gold Corporation and changed its name to IAMGOLD Corporation in June 1997. IAMGOLD Corporation was founded in 1990 and is headquartered in Toronto, Canada..

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

Contributing Sources

---